Welcome to our dedicated page for Protara Therapeutics SEC filings (Ticker: TARA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Protara Therapeutics, Inc. filings document a Nasdaq-listed, Delaware clinical-stage biotechnology company developing TARA-002 for non-muscle invasive bladder cancer and lymphatic malformations, and IV Choline Chloride for patients receiving parenteral support. Form 8-K disclosures include clinical-data updates, Regulation FD materials, financial results, investor presentations, and business updates related to the company's investigational programs.
The filing record also covers Protara's capital structure and governance, including common stock registered on The Nasdaq Global Market, public offering and underwriting agreements, warrant-related disclosures, and proxy materials for annual stockholder voting. Proxy filings describe board elections, executive compensation matters, equity plans, audit oversight, and other corporate-governance proposals.
Protara Therapeutics director Barry P. Flannelly received a grant of stock options covering 31,000 shares of common stock. The options have an exercise price of $3.94 per share and expire on June 14, 2036.
According to the grant terms, the 31,000 options vest in full on the first anniversary of the June 15, 2026 grant date, as long as the director continues serving on the board, and they vest in full upon a Change of Control.
Protara Therapeutics director Luke M. Beshar received a grant of stock options covering 31,000 shares of common stock. These options have an exercise price of $3.94 per share and were awarded as compensation, not purchased in the open market.
The options were granted as an Annual Grant and will vest in full on the first anniversary of the grant date, as long as he continues serving on the board through that date. They will also vest in full upon a Change of Control, if that occurs earlier.
Protara Therapeutics, Inc. held its Annual Meeting of Stockholders, where all seven proposals received stockholder approval. Stockholders elected three Class III directors to serve until the 2029 annual meeting and ratified Ernst & Young LLP as independent auditor for the year ending December 31, 2026.
Stockholders approved, on an advisory basis, executive compensation and set the say‑on‑pay vote frequency at one year. They also approved an amendment to the 2024 Equity Incentive Plan and an amendment to increase authorized common shares from 100,000,000 to 200,000,000. An additional charter amendment allowing officer exculpation, as permitted by Delaware law, was also approved.
Protara Therapeutics, Inc. Chief Commercial Officer William Conkling reported a routine tax-related share disposition. On June 2, 2026, 6,008 shares of common stock were withheld by the company at $4.34 per share to cover income tax obligations from the vesting of Restricted Stock Unit Awards granted on June 2, 2025. After this withholding, Conkling directly holds 69,992 shares of Protara common stock. This transaction was not an open-market purchase or sale, but an administrative step tied to equity compensation.
Protara Therapeutics (TARA) has filed a prospectus supplement to sell up to $100,000,000 of common stock through an at-the-market sales agreement with TD Securities (USA) LLC (TD Cowen). Shares may be sold from time to time under the Sales Agreement, which permits sales on Nasdaq or by other methods permitted by law.
This offering is part of a $300,000,000 shelf registration. The prospectus supplement states last reported sale price of $5.27 per share on May 11, 2026 and uses proceeds to fund clinical development of TARA-002, IV Choline Chloride and other programs. The Sales Agreement allows TD Cowen to act as agent or principal, with compensation up to 3.0% of gross proceeds, and contains customary indemnification provisions.
Janus Henderson Group plc reports beneficial ownership of 5,207,011 shares of Protara Therapeutics, Inc. common stock, representing 9.6% of the class. The holdings are reported on behalf of multiple investment advisers that exercise shared voting and dispositive power for managed portfolios.
The filing notes that the Managed Portfolios generally exercise investment and voting discretion but do not have rights to receive dividends or sale proceeds; the Janus Henderson Biotech Innovation Master Fund Ltd. holds the right to receive dividends or proceeds for more than 5% of the class. The amendment is signed on 5/15/2026.
Protara Therapeutics, Inc. has registered a shelf to offer up to $300,000,000 of common stock, preferred stock, debt securities and/or warrants.
The prospectus states the registration includes $110,914,137.87 of unsold securities from a prior registration and that specific terms and proceeds treatment will be set forth in future prospectus supplements. The company notes its Nasdaq symbol is TARA and that its common stock last traded at $5.27 per share on May 11, 2026. The filing reiterates that proceeds will be used for general corporate purposes, including research and development, clinical trials and working capital.
Protara Therapeutics reported a wider net loss for the three months ended March 31, 2026 as it accelerated investment in its pipeline. Net loss was $17.8 million versus $11.9 million a year earlier, driven by higher research and development spending of $13.6 million and general and administrative costs of $6.1 million.
The company ended the quarter with $177.4 million in unrestricted cash, cash equivalents and marketable debt securities and believes this will fund operations for at least 12 months. Protara advanced multiple programs, including TARA-002 for non-muscle invasive bladder cancer with promising complete response rates, TARA-002 for pediatric lymphatic malformations with interim clinical success in STARBORN-1, and initiated the registrational THRIVE-3 Phase 3 trial for IV Choline Chloride in long-term parenteral support patients.
Protara Therapeutics reported a larger net loss as it advances its pipeline. For the quarter ended March 31, 2026, the company recorded a net loss of $17.8 million, compared with $11.9 million a year earlier, driven by higher research and development and general and administrative expenses.
Research and development spending rose to $13.6 million, while general and administrative costs were $6.1 million. Protara ended the quarter with cash, cash equivalents and investments of approximately $177 million, which it expects will fund operations into 2028.
Clinically, the company plans to submit a Biologics License Application for TARA‑002 in lymphatic malformations in the second half of 2027, and aims to complete enrollment of the BCG‑unresponsive registrational cohort of the ADVANCED‑2 bladder cancer trial and start the ADVANCED‑3 registrational trial in BCG‑naïve patients in the second half of 2026. It also expects multiple data readouts in 2026, including interim TARA‑002 data and interim THRIVE‑3 IV Choline Chloride results.